CN105434511B - A kind of hymsleya amabilis medicine materical crude slice and its preparation method and application - Google Patents
A kind of hymsleya amabilis medicine materical crude slice and its preparation method and application Download PDFInfo
- Publication number
- CN105434511B CN105434511B CN201410411862.3A CN201410411862A CN105434511B CN 105434511 B CN105434511 B CN 105434511B CN 201410411862 A CN201410411862 A CN 201410411862A CN 105434511 B CN105434511 B CN 105434511B
- Authority
- CN
- China
- Prior art keywords
- hymsleya amabilis
- amabilis
- hymsleya
- radix glycyrrhizae
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 42
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 13
- 235000011477 liquorice Nutrition 0.000 claims description 13
- 239000002893 slag Substances 0.000 claims description 13
- 230000000202 analgesic effect Effects 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 241000906682 Hemsleya Species 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 241001529246 Platymiscium Species 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 210000004709 eyebrow Anatomy 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 241000466337 Hemsleya omeiensis Species 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 241000466329 Hemsleya gigantha Species 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 29
- 238000002474 experimental method Methods 0.000 abstract description 25
- 208000002193 Pain Diseases 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 235000019658 bitter taste Nutrition 0.000 abstract description 8
- 230000036407 pain Effects 0.000 abstract description 8
- 230000001988 toxicity Effects 0.000 abstract description 8
- 231100000419 toxicity Toxicity 0.000 abstract description 8
- 238000012545 processing Methods 0.000 abstract description 7
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 abstract description 5
- 231100000614 poison Toxicity 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 235000009508 confectionery Nutrition 0.000 abstract description 3
- 239000003440 toxic substance Substances 0.000 abstract description 3
- 208000005392 Spasm Diseases 0.000 abstract description 2
- 230000000146 antalgic effect Effects 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 239000002574 poison Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 69
- 230000036541 health Effects 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000011049 filling Methods 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 208000000114 Pain Threshold Diseases 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 231100000403 acute toxicity Toxicity 0.000 description 5
- 230000007059 acute toxicity Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000037308 hair color Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 244000157790 Buglossoides arvense Species 0.000 description 2
- 235000004256 Buglossoides arvense Nutrition 0.000 description 2
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 241000244987 Daiswa polyphylla Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 241000825107 Hierochloe Species 0.000 description 1
- 235000015466 Hierochloe odorata Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of drug or Halth-care composition containing hymsleya amabilis, it is the preparation being prepared by the raw material of following weight proportion: 100 parts of hymsleya amabilis, 5-35 parts of Radix Glycyrrhizae.The present invention also provides a kind of hymsleya amabilis medicine materical crude slice, it is to be processed with raw material hymsleya amabilis with Radix Glycyrrhizae, wherein hymsleya amabilis, Radix Glycyrrhizae weight proportion are as follows: 100 parts of hymsleya amabilis, 5-35 parts of Radix Glycyrrhizae.The present invention also provides the preparation method of the hymsleya amabilis medicine materical crude slice and purposes.Hymsleya amabilis medicine materical crude slice of the present invention is processed by succus liquiritiae, to alleviate bitter taste, dispel mild toxicity, make full use of Radix Glycyrrhizae sweet in flavor, it is mild-natured, has the function of clearing heat and detoxicating, relieving spasm to stop pain, reach flavoring, the processing purpose of removing toxic substances, different proportion solution bitter taste is tasted with mouth simultaneously, influence of the succus liquiritiae processing to Xue Dan Solution poison synergy is investigated with anti-inflammatory and antalgic and acute toxicity testing, and process the content of front and back using Hemsleyadin first as index observing succus liquiritiae, experiments have shown that hymsleya amabilis can mitigate pharmacological property after succus liquiritiae system, toxicity is reduced, while the bitter taste of hymsleya amabilis can be mitigated with flavoring.
Description
Technical field
The present invention relates to hymsleya amabilis medicine materical crude slice.
Background technique
Hymsleya amabilis is the dried root of Curcurbitaceae hymsleya amabilis platymiscium dolichocarpel hemsleya root, high eyebrow hymsleya amabilis or huge colored hymsleya amabilis.Bitter in taste,
It is cold.It is slightly poisonous.With clearing heat and detoxicating, the effect of anti-inflammatory analgetic.It is usually used in having a stomachache, canker, the infection of the upper respiratory tract, bronchus
Inflammation, pneumonia, bacillary dysentery, enteritis, urinary infection, septicemia and other multi-infections.
The report that the current effective component for extract in hymsleya amabilis or hymsleya amabilis is prepared into preparation is more, such as application number:
200810044933.5, denomination of invention: a kind of compound hemsleyadin preparation, the present invention relates to a kind of compound Chinese medicinal preparations, specially
A kind of compound hemsleyadin preparation.A kind of compound hemsleyadin preparation is made of Hemsleyadin, glycyrrhizic acid, Asian puccoon glycosides, and formula is hymsleya amabilis
Plain 2.5 milligrams, 1.25 milligrams of glycyrrhizic acid, 1.25 milligrams of Asian puccoon glycosides.Preparation formulation is effervescent tablet or suppository.Invention formulation is outer
It is administered with cavity, effect affected part is direct, and ingredient is small to body stimulation, and course for the treatment of section, curative effect are fast, and pathogen-free domestic drug resistance feelings are used for a long time
Condition occurs, and has special efficacy to diseases such as gynecology colpitis, cervical erosion.Application number: 03159059.4, denomination of invention: Yi Zhongzhi
The drug for treating enterogastric diseases, the invention discloses a kind of drug for treating enterogastric diseases, it be selection mainly include hymsleya amabilis,
The Chinese medicines such as Paris polyphylla, evodia rutaecarpa, radix aucklandiae, rhizoma corydalis, bletilla, cuttlebone, Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Radix Codonopsis, Radix Astragali and Radix Glycyrrhizae are combined,
So that each efficacy of drugs generates synergistic effect, to effectively treat enterogastric diseases.It can be prepared to any normal
Use internal dosage form.The present invention has the effects that apparent Antiulcer activity, stronger spasmolysis and analgesia, apparent anti-inflammatory and one
The effect of fixed tonneau is defecated, and safe without toxic side effect very good to curative effects such as digestive tract ulcer, gastritis and enteritis.
Summary of the invention
The technical solution of the present invention is to provide hymsleya amabilis medicine materical crude slice, there is provided hymsleya amabilis drinks for another technical solution of the invention
The preparation method and use of piece.
The present invention provides a kind of drug or Halth-care compositions, it is prepared by the raw material of following weight proportion
Preparation:
100 parts of hymsleya amabilis, 5-35 parts of Radix Glycyrrhizae.
Further preferably, it is the preparation being prepared by the raw material of following weight proportion:
100 parts of hymsleya amabilis, 25 parts of Radix Glycyrrhizae.
Wherein, the hymsleya amabilis derives from Curcurbitaceae hymsleya amabilis platymiscium dolichocarpel hemsleya root Hemsleya dolichocarpa
W.J.Chang, the colored hymsleya amabilis Hemsleya of high eyebrow hymsleya amabilis Hemsleya omeiensis L.T.Shen et W.J.Chang or huge
The dried root of gigantha W.J.Chang.Pharmaceutical composition of the present invention is that by hymsleya amabilis, the primary medicinal powder of Radix Glycyrrhizae or water or have
Solvent extract is active constituent, and the system that pharmaceutically or acceptable auxiliary material or auxiliary material ingredient are prepared on food is added
Agent.
Wherein, the preparation is oral solution, tablet, capsule, pill, granule, medicinal tea.
The present invention also provides a kind of hymsleya amabilis medicine materical crude slice, it is to be processed with raw material hymsleya amabilis with Radix Glycyrrhizae, wherein hymsleya amabilis, Radix Glycyrrhizae
Weight proportion are as follows:
100 parts of hymsleya amabilis, 5-35 parts of Radix Glycyrrhizae.
It is further preferred that the weight proportion of the hymsleya amabilis Radix Glycyrrhizae are as follows:
100 parts of hymsleya amabilis, 25 parts of Radix Glycyrrhizae.
The present invention also provides a kind of methods for preparing the hymsleya amabilis medicine materical crude slice, it includes the following steps:
A, extracting liquorice is added water to cook and is removed slag；
B, hymsleya amabilis is added, bored profit 1.5-3h exhausts to succus liquiritiae, 35-60 DEG C of drying.
The present invention also provides the hymsleya amabilis medicine materical crude slice purposes in preparing anti-inflammatory drugs.
The present invention also provides the hymsleya amabilis medicine materical crude slice to prepare the purposes in analgesic.
Hymsleya amabilis medicine materical crude slice of the present invention is processed by succus liquiritiae, to alleviate bitter taste, is dispelled mild toxicity, is made full use of Radix Glycyrrhizae sweet in flavor, property
It is flat, have the function of clearing heat and detoxicating, relieving spasm to stop pain, reaches flavoring, the processing purpose of removing toxic substances, while different proportion solution hardship is tasted with mouth
Taste investigates influence of the succus liquiritiae processing to hymsleya amabilis removing toxic substances synergy with anti-inflammatory and antalgic and acute toxicity testing, and is with Hemsleyadin first
Index observing succus liquiritiae processes the content of front and back, experiments have shown that hymsleya amabilis can mitigate pharmacological property after succus liquiritiae system, reduces toxicity, simultaneously
The bitter taste of hymsleya amabilis can be mitigated with flavoring.
Detailed description of the invention
Fig. 1 Hemsleyadin first reference substance map
Fig. 2 health product HPLC map
Fig. 3 product HPLC map
Specific embodiment
The preparation of the hymsleya amabilis processed product of the present invention of embodiment 1
Extracting liquorice piece or fragment add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis is added, and bored profit 2h exhausts to succus liquiritiae, and 40 DEG C
Drying.
The preparation of the hymsleya amabilis capsule of the present invention of embodiment 2
Extracting liquorice piece or fragment add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis is added, and bored profit 2h exhausts to succus liquiritiae, and 40 DEG C
Drying；Beat powder, cross No. six sieve, medicinal powder be packed into 1# capsule shells, every dress 0.3g, pack to get.
The preparation of the medicinal granule of the present invention of embodiment 3
Extracting liquorice piece or fragment add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis is added, and bored profit 2h exhausts to succus liquiritiae, and 40 DEG C
Drying.
Hymsleya amabilis medicine materical crude slice processed is taken, 25 times of amount water are added, decocts 3 times, 1 hour every time, merges medical fluid, filtration is dense in 60 DEG C of decompressions
After contracting, constant pressure and dry, gained extract powder adds appropriate dextrin (ratio 1:0.67), mixes, and adds appropriate 75% ethyl alcohol adjustment humidity,
Uniform particle is made with fashion of extrusion by 14 meshes in the softwood that " hand is pinched agglomerating, flicking and dissipated " is made, dry, whole grain,
Packaging to get.
The preparation of the medicinal tablet of the present invention of embodiment 4
Extracting liquorice piece or fragment add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis is added, and bored profit 2h exhausts to succus liquiritiae, and 40 DEG C
Drying.
Hymsleya amabilis medicine materical crude slice processed is taken, 25 times of amount water are added, decocts 3 times, 1 hour every time, merges medical fluid, filtration is dense in 60 DEG C of decompressions
After contracting, constant pressure and dry, gained extract powder adds appropriate lactose as filler, and 50% ethyl alcohol is wetting agent, tabletting, sugar coating, i.e.,
?.
The preparation of the hymsleya amabilis tea bag of the present invention of embodiment 5
Hymsleya amabilis 100g, Radix Glycyrrhizae 25g are taken, mixes, beats powder, is sieved, pack is prepared into tea bag.
The hymsleya amabilis processed product prescription screening test of the present invention of embodiment 6
1. different proportion Radix Glycyrrhizae influences to study on hymsleya amabilis bitter taste
The research of influence of this experiment by the dosage of Radix Glycyrrhizae to hymsleya amabilis bitter taste, determines the optimum amount of succus liquiritiae.
1 extracting liquorice piece of concocting method or fragment, add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis, bored profit 2h, to succus liquiritiae is added
Exhaustion, 40 DEG C of drying.
Every net hymsleya amabilis of 100kg, with Radix Glycyrrhizae 5kg.
2 extracting liquorice piece of concocting method or fragment, add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis, bored profit 2h, to succus liquiritiae is added
Exhaustion, 40 DEG C of drying.
Every net hymsleya amabilis of 100kg, with Radix Glycyrrhizae 10kg.
3 extracting liquorice piece of concocting method or fragment, add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis, bored profit 2h, to succus liquiritiae is added
Exhaustion, 40 DEG C of drying.
Every net hymsleya amabilis of 100kg, with Radix Glycyrrhizae 25kg.
4 extracting liquorice piece of concocting method or fragment, add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis, bored profit 2h, to succus liquiritiae is added
Exhaustion, 40 DEG C of drying.
Every net hymsleya amabilis of 100kg, with Radix Glycyrrhizae 35kg.
As a result: orally tasting, 1 taste of concocting method is extremely bitter, and 2 bitter of concocting method, concocting method 3 is lightly seasoned, and 4 taste of concocting method is micro-
Sweet tea.Therefore, 25% Radix Glycyrrhizae (using in terms of hymsleya amabilis) is selected to take juice as the dosage for processing hymsleya amabilis.(25% Radix Glycyrrhizae, that is, every 100kg is net
Hymsleya amabilis, with Radix Glycyrrhizae 25kg.Succus liquiritiae 25kg is prepared with Radix Glycyrrhizae 25kg.)
Influence of the 1 succus liquiritiae dosage of table for hymsleya amabilis taste
2 process front and back Hemsleyadin first changes of contents
Hymsleya amabilis mainly contains Hemsleyadin first and a small amount of Hemsleyadin second and saponin constituent, modern pharmacological studies have shown that Hemsleyadin has
There are a variety of pharmacological activity such as antitumor, antiviral, antibacterial, protection stomach.Existing germ experiment illustrates that Hemsleyadin first can inhibit gold
The synthesis of the cell wall of staphylococcus aureus, antibacterial action are obvious.Meanwhile intravenous injection Hemsleyadin first 40mg (intraperitoneal injection) is right
Fever caused by rabbit injection typhoid fever typhoid fever first mixed vaccine has slight antipyretic effect.Therefore, this experimental selection Hemsleyadin first
The index components of front and back changes of contents are processed as hymsleya amabilis.
2.1 instruments and reagent
Japanese Shimadzu LC-20AT efficient liquid phase system (DAD detector SPD-M20A230V), BP211D electronics point
It analyses balance (sensibility reciprocal 0.00001g, German Sartorius company), KQ-300E ultrasonic cleaning machine (the limited public affairs of city of Kunshan's ultrasonic instrument
Department)；BP-61 electronic balance (sensibility reciprocal 0.0001g, German Sartorius company).
2.2 experiments and result
2.2.1 chromatographic condition
Chromatographic column: Thermo BDS HYPERSIL C18 column (4.6mm × 250mm, 5 μm), mobile phase: acetonitrile-water (28:
72), sample volume: 10 μ L；Flow velocity: 1mL/min；Column temperature: 25 DEG C；Detection wavelength: 212nm.
2.2.2 prepared by reference substance solution
It is appropriate that precision weighs Hemsleyadin first reference substance, sets in 10mL volumetric flask, methanol dissolves and is settled to scale.
2.2.3 prepared by test solution
The Radix Glycyrrhizae of accurately weighed 1g25% processes hymsleya amabilis sample and sets in stuffed conical flask, precision addition methanol 40mL, close plug,
Weighed weight is ultrasonically treated (power 250W, frequency 40kHz), lets cool, then weighed weight, the weight of less loss is supplied with methanol, is shaken
Even, with 0.45 μm of filtering with microporous membrane, filtrate is test solution, spare.
2.2.4 Precision Experiment
Precision Experiment records Hemsleyadin first peak area with same concentration standard items continuous 6 times.
2 Hemsleyadin first precision experiment result of table
As a result: Hemsleyadin first peak area RSD is 1.66%, illustrates that instrument precision is good.
2.2.5 stability experiment
Sample stability experiment, with the solution after sample extraction, sample introduction is measured in different time points, record Hemsleyadin first
Peak area, to assess the stability of sample.
3 stability experiment result of table
As a result: Hemsleyadin first peak area RSD is 1.10%, illustrates to have good stability within the 12h of sample after extraction.
2.2.6 repeated experiment
6 parts of same sample parallel extraction are taken, injection instrument analysis records Hemsleyadin first peak area.
4 Hemsleyadin first precision experiment result of table
As a result: Hemsleyadin first RSD is 2.09%, illustrates that the reproduction of sample extraction method is linearly good.
2.2.7 sample recovery rate
Sample-adding recovery test is the accuracy for investigating sample measurement result, halves 6 parts of sample for weighing known content, is added
A certain amount of reference substance participates in extraction process, and extracting solution injects liquid chromatograph and records experimental data, calculates actually measured amount
Subtract the ratio for the amount that the amount in known sample is added with reference substance again.
5 Hemsleyadin first of table is loaded recovery experiment result
As a result: according to formula obtain Hemsleyadin first sample recovery rate be 96.51%~101.70% the data obtained accuracy compared with
It is high.
2.2.8 process front and back sample Hemsleyadin first assay (see Fig. 1-Fig. 3)
6 health product Hemsleyadin first content results of table
7 product Hemsleyadin first content results of table
The content of health product Hemsleyadin first be 0.1639%~0.1727%, product hymsleya amabilis cellulose content be 0.1526%~
0.1649%, the results showed that hymsleya amabilis content of Hemsleyadin first after succus liquiritiae system decreases.
Beneficial effects of the present invention are proved below by way of specific pharmacodynamics test.
The 1 anti-inflammatory experiment of drug of the present invention of test example
1 experimental animal
Cleaning grade kunming mice, 18~22g of weight are provided by Sichuan up to large animal experimental center.Experimental animal production
Credit number: SCXK (river) 2013-24.
2 experiment reagents
Health product: taking hymsleya amabilis sample, adds 10 times of amount water, extracts 2 times, each 30min, and filtering, filtrate is concentrated into containing hymsleya amabilis
0.2g/ml and 0.1g/ml, respectively high dose group and low dose group, for use.
Processed product: extracting liquorice piece or fragment add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis is added, micro- dry with being fried with slow fire, and take
Out, it dries.
Every net hymsleya amabilis of 100kg, with Radix Glycyrrhizae 25kg.
Above-mentioned processed product is taken, 10 times of amount water are added, is extracted 2 times, each 30min, filtering, filtrate is concentrated into containing to containing hymsleya amabilis
0.2g/ml and 0.1g/ml, respectively high dose group and low dose group, for use.
Aspirin suspension: aspirin (Shijiazhuang Kang Li pharmaceutcal corporation, Ltd, lot number 120923) beats powder, crosses 100
Mesh is configured to the suspension that concentration is 0.025g/mL with distilled water, spare.
3 experimental methods and result
The influence of 3.1 paraxylene induced mice auricle edemas
Kunming mice takes male 60, is randomly divided into: physiological saline group, aspirin group (0.5g/kg), hymsleya amabilis health product are high
((2g/kg), hymsleya amabilis process product high dose group (4g/kg), hymsleya amabilis processs product low dosage for dosage group (4g/kg), hymsleya amabilis health product low dose group
Group ((2g/kg) dosage group, every group 10, groups of animals is with relative medicine 0.2ml/10g stomach-filling, once a day, continuous 3d, end
After secondary stomach-filling 2h, 0.15ml caused by dimethylbenzene xylene inflammation is uniformly smeared in auris dextra auricle tow sides, is put to death after 45min, cuts left and right two
Ear is punched in two auricle same position of mouse or so with the punch of diameter 9mm and is sampled, weighed in time, according to following formula
It calculates:
Swelling and inhibiting rate (%): inhibiting rate=(physiological saline group swelling-administration group swelling)/physiological saline
Group swelling × 100%
Swelling=auris dextra slice weight-auricle weight
8 hymsleya amabilis of table processes the influence of front and back paraxylene induced mice auricle inflammation
Note: P < 0.01 * P < 0.05 compared with blank group, * *；Compared with equal dosage hymsleya amabilis health product,#P < 0.05,##P<0.01。
The result shows that hymsleya amabilis, which processes mice auricle swelling caused by the paraxylene of front and back, one compared with blank group
Fixed inhibiting effect (P < 0.01).Compared with same dosage hymsleya amabilis health product, hymsleya amabilis processs suppression of the product high dose group to mice auricle swelling
Production, which is used, has significant difference (P < 0.05), low dose group no difference of science of statistics, but hymsleya amabilis processs product low dosage as the result is shown
Therapeutic effect is more preferable.
3.2 pairs of egg whites cause the influence of rat paw edema
Kunming mice, male, is randomly divided by 60: physiological saline group, aspirin group (0.5g/kg), hymsleya amabilis health product are high
((2g/kg), hymsleya amabilis process product high dose group (4g/kg), hymsleya amabilis processs product low dosage for dosage group (4g/kg), hymsleya amabilis health product low dose group
Group ((2g/kg) dosage group, every group 10, groups of animals is with relative medicine 0.2ml/10g stomach-filling, once a day, continuous 3d, end
It is subcutaneously injected into the clear 0.1ml of 10% Fresh Egg from the middle part of rat paw after secondary 0.5~1h of stomach-filling, 1 after injection, 2,3,4h
Its right metapedes volume is measured in aforementioned manners, is calculated pedal swelling rate, is compared the difference condition of control group and administration group, as a result see
Table
Pedal swelling rate (%)=(the original sufficient volume of each time point foot volume-after swelling)/original sufficient volume × 100%
9 hymsleya amabilis of table processes the influence that front and back causes rat paw edema to egg white
Note: P < 0.01 * P < 0.05 compared with blank group, * *；Compared with equal dosage hymsleya amabilis health product,#P < 0.05,##P<0.01。
The result shows that hymsleya amabilis processes front and back to rat paw edema degree caused by egg white in 1~4h compared with blank group
Inside there is certain inhibiting effect (P < 0.05~0.01), and analgesic effect enhances as time went on；With equal dosage hymsleya amabilis
Health product compares, and hymsleya amabilis processs inhibiting effect of the product to rat paw edema, and there were significant differences (P < 0.05~0.01), and toast product effect is more
By force, and it is rapid-action, long action time.
The experiment of the medicine analgesic of the present invention of test example 2
1 experimental animal
Cleaning grade kunming mice, 18~22g of weight are provided by Sichuan up to large animal experimental center.Experimental animal production
Credit number: SCXK (river) 2013-24.
2 experiment reagents
Health product: taking hymsleya amabilis sample, adds 10 times of amount water, extracts 2 times, each 30min, and filtering, filtrate is concentrated into containing hymsleya amabilis
0.2g/ml and 0.1g/ml, respectively high dose group and low dose group, for use.
Processed product: extracting liquorice piece or fragment add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis is added, micro- dry with being fried with slow fire, and take
Out, it dries.
Every net hymsleya amabilis of 100kg, with Radix Glycyrrhizae 25kg.
Above-mentioned processed product is taken, 10 times of amount water are added, is extracted 2 times, each 30min, filtering, filtrate is concentrated into 0.2g/ containing hymsleya amabilis
Ml and 0.1g/ml, respectively high dose group and low dose group, for use.
Aspirin suspension: aspirin (Shijiazhuang Kang Li pharmaceutcal corporation, Ltd, lot number 120923) beats powder, crosses 100
Mesh is configured to the suspension that concentration is 0.025g/mL with distilled water, spare.
2.1 hot plate method
Screening qualified mice: mouse is from being placed on the hot plate pain value of (second) as the mouse the time required to there is licking metapedes
Valve.It is all to lick the metapedes time less than 5s or abandon it greater than 30s or leaper.
Mouse 60, female, hymsleya amabilis health product high dose group (4g/kg), ((2g/kg), the hymsleya amabilis toast of hymsleya amabilis health product low dose group
Product high dose group (4g/kg), hymsleya amabilis process product low dose group ((2g/kg) dosage group, control group (physiological saline), positive controls
With aspirin 0.5g/kg, the pain threshold for first measuring every mouse before administration twice, takes average value twice as the preceding threshold of pain is administered
Value.Each group gastric infusion, stomach-filling volume are (10ml/kg).Successive administration 3d, last mouse is according to dosage after gastric infusion 30min,
Mouse is put into hot plate pain threshold detector, hot plate temperature is (55 ± 0.5) DEG C, puts into hot plate to the time for occurring licking metapedes from mouse
For the pain threshold of the mouse, primary (60s is still reactionless, in terms of 60s) is surveyed every 30min (4 times), average pain threshold is found out and unites
Meter.
Average pain threshold before threshold of pain increase rate=(average pain threshold before average pain threshold-medication after medication)/medication ×
100%
10 hymsleya amabilis of table processes influence of the front and back to thermostimulation induced mice pain
Note: P < 0.01 * P < 0.05 compared with blank group, * *；Compared with equal dosage hymsleya amabilis health product,#P < 0.05,##P<0.01。
The result shows that in addition to 30min, hymsleya amabilis, which processes front and back, mice pain caused by thermostimulation compared with blank group
Certain inhibiting effect (P < 0.05~0.01)；Compared with equal dosage hymsleya amabilis health product, the analgesic effect of hymsleya amabilis toast product is aobvious after 30min
The enhancing of work property, and persistent.
2.2 writhing method
Mouse 120, half male and half female, physiological saline group, aspirin group (0.5g/kg), hymsleya amabilis health product high dose group
((2g/kg), hymsleya amabilis process product high dose group (4g/kg), hymsleya amabilis processs product low dose group for (4g/kg), hymsleya amabilis health product low dose group
((2g/kg) dosage group, every group 10, each group gastric infusion, one time a day, continuous 3d, 1h, each mouse are injected intraperitoneally after the last administration
0.6% acetic acid 0.1mL/10g, record calculate analgesia to occurring the number of animals of writhing response and writhing number in 15min after acetic acid
Rate.
Analgesia writhing rate=(control group writhing response number-administration group writhing response number)/control group writhing response mouse
Number × 100%
11 hymsleya amabilis of table processes the influence that front and back Dichlorodiphenyl Acetate causes mouse writhing reaction
Note: P < 0.01 * P < 0.05 compared with blank group, * *；Compared with equal dosage hymsleya amabilis health product,#P < 0.05,##P<0.01。
The result shows that positive drug group, hymsleya amabilis health product are high, toast product high dose group Dichlorodiphenyl Acetate causes mouse to turn round compared with blank group
Body has certain analgesic activity (P < 0.05~0.01), illustrates that hymsleya amabilis has certain analgesic activity；With equal dosage hymsleya amabilis health product
Compare, hymsleya amabilis, which processs product, has significant difference to the analgesic activity of mouse, illustrates that hymsleya amabilis toast product are stronger to the analgesic activity of mouse.
Test example 3 processes front and back hymsleya amabilis acute toxicity test research
1 experimental animal
Cleaning grade kunming mice, half male and half female, 18~22g of weight are provided by Sichuan up to large animal experimental center.Experiment
Animal productiong licensing number: SCXK (river) 2013-24.
2 experiment reagents
Processed product: extracting liquorice piece or fragment add suitable quantity of water, and decoction is removed slag, and net hymsleya amabilis is added, micro- dry with being fried with slow fire, and take
Out, it dries.
Every net hymsleya amabilis of 100kg, with Radix Glycyrrhizae 25kg.
Medical fluid preparation:
Hymsleya amabilis sample is taken, 10 times of amount water are added, is extracted 2 times, each 30min, filtering, filtrate is concentrated into 2g/ml containing hymsleya amabilis and waits for
With.
Referring to classical acute toxicity (oral median lethal dose LD50, maximal tolerance dose MTD, maximum dosage-feeding MLD) test
Method is processed front and back hymsleya amabilis toxicity comparative studies.
3 experimental methods and result
3.1 different component sample Mouse Acute Toxicity trial tests
The preceding fasting 12h mouse of test is taken, be randomly divided into 3 groups by weight and gender: hymsleya amabilis health product group, hymsleya amabilis process product group and sky
Bai Zhao group, every group 6.Medicine group presses 40gkg-1Administration, the isometric physiological saline of blank control group stomach-filling carry out LD50Value
Measurement.It is difficult to measure LD50Value, by 40gkg-1Multiple gastric infusion carries out the survey of MTD and MLD value within mouse weight 1 day
It is fixed.
Preliminary result shows: hymsleya amabilis health product group, hymsleya amabilis toast product group and blank photo group are limited by administered volume and concentration,
It is difficult to measure LD50It is worth, toxic sex expression and death after intragastric administration on mice, therefore carries out the measurement of MTD value.It is carried out according to trial test result
Formal test.
3.2 acute toxicity MTD formal tests
Above-mentioned mouse 60 is taken, it is every to be randomly divided into hymsleya amabilis health product group, hymsleya amabilis toast product group and blank photo group by weight and gender
Group 20.After being deprived of food but not water 12h before mouse test, administration group presses 20gkg-1It mouse weight gastric infusion 1 time, calculates 1
Interior dosage, the isometric water of water control group stomach-filling carry out acute toxicity test observation.
Observed after administration the behavioral activity of mouse, the state of mind, coat, ingest, drink water, breathing, excrement situation and nose,
Eye, situations such as whether there is or not abnormal secretion, death and changes of weight in oral cavity.It is observed continuously 14 days, observes its acute toxic symptoms spectrum,
Record accumulation death toll and mouse weight variation.Dead animal performs an autopsy on sb. at once, visually observe its main organs (heart, brain,
Liver,spleen,kidney, lung) variation, discovery diseased organ then carry out Pathomorphologic check.
Table 12 processes front and back hymsleya amabilis acute toxicity MTD and reports situations
14d is observed continuously, the results showed that, compared with control group mice, hymsleya amabilis process the diet of product group test mice, hair color,
Activity and stool and urine are normal.Eye, nose, oral cavity no abnormality seen secretion, no ill symptoms occur；Hymsleya amabilis health product group test mice
Four limbs activity and diet drinking-water are normal, but the phenomenon that hair color is not magnificent, and excrement is at scattered paste shape occur, and mouse death occur, through solving
Discovery is cutd open, is not that stomach-filling causes.
Table 13 processes front and back hymsleya amabilis acute toxicity MTD body weight increase situation
Note: P < 0.01 * P < 0.05 compared with blank group, * *；Compared with equal dosage hymsleya amabilis health product,#P < 0.05,##P<0.01。
The result shows that compared with blank group, hymsleya amabilis health product, toast product group mouse weight growth rate be after stomach-filling 7d
Decline (P < 0.05), illustrates that hymsleya amabilis has a certain impact to mouse weight growth；Compared with equal dosage hymsleya amabilis health product, hymsleya amabilis processs product
Influence to mouse weight growth rate is relatively low (P < 0.05).
The main organs such as each group experiment mice heart, lung, liver, kidney, stomach, spleen are dissected, visually observes and is showed no abnormality.
As a result, it has been found that: to intragastric administration on mice hymsleya amabilis health product and toast product through MTD experiment investigation, hymsleya amabilis health product group MTD value is
20.0g·kg-1·d-1, water, which is respectively equivalent to 133 times of clinical 60kg people's per kilogram of body weight consumption per day, has certain toxicity,
Main acute signs of toxicity has diarrhea, hair color not magnificent hymsleya amabilis toast product group mouse diet, hair color, activity after intragastric administration on mice hymsleya amabilis health product
And stool and urine is normal, MTD value is greater than 20.0gkg-1·d-1, illustrate that hymsleya amabilis MTD after processing becomes larger, toxicity reduces.
It discusses
Influence of this experiment by the Radix Glycyrrhizae to 5%, 15%, 25%, 35% to hymsleya amabilis bitter taste, final choice 25% it is sweet
Grass is as the best materials processed.Anti-inflammatory and analgesic the experimental results showed that, hymsleya amabilis health product, toast product have certain anti-inflammatory and town
Pain acts on, while after succus liquiritiae is processed, the enhancing of anti-inflammatory and analgesic activity.Acute toxicity testing the result shows that, but between the two
There was no significant difference.Hymsleya amabilis health product group MTD value is 20.0gkg-1·d-1, but after succus liquiritiae is processed, MTD value is greater than
20.0g·kg-1·d-1, illustrate that hymsleya amabilis MTD after processing becomes larger, toxicity reduces.
Claims (8)
1. a kind of drug or Halth-care composition containing hymsleya amabilis, it is characterised in that: it is the raw material preparation by following weight proportion
Made of preparation:
100 parts of hymsleya amabilis, 25 parts of Radix Glycyrrhizae.
2. composition according to claim 1, it is characterised in that: the hymsleya amabilis is long from Curcurbitaceae hymsleya amabilis platymiscium
Fruit hymsleya amabilis Hemsleya dolichocarpa W.J.Chang, high eyebrow hymsleya amabilis Hemsleya omeiensis L.T.Shen et
The dried root of the colored hymsleya amabilis Hemsleya gigantha W.J.Chang of W.J.Chang or huge.
3. composition according to claim 1 or 2, it is characterised in that: it is by the primary medicinal powder or water of hymsleya amabilis, Radix Glycyrrhizae
Or extractive with organic solvent is active constituent, pharmaceutically or on food acceptable auxiliary material or auxiliary material ingredient are prepared for addition
Preparation.
4. composition according to claim 3, it is characterised in that: the preparation is oral solution, tablet, capsule, ball
Agent, granule, medicinal tea.
5. a kind of hymsleya amabilis medicine materical crude slice, it is to be processed with raw material hymsleya amabilis with Radix Glycyrrhizae, wherein hymsleya amabilis, Radix Glycyrrhizae weight proportion are as follows:
100 parts of hymsleya amabilis, 25 parts of Radix Glycyrrhizae.
6. a kind of method for preparing hymsleya amabilis medicine materical crude slice described in claim 5, it includes the following steps:
A, extracting liquorice is added water to cook and is removed slag, and prepares succus liquiritiae；
B, hymsleya amabilis is added, bored profit exhausts to succus liquiritiae, drying.
7. hymsleya amabilis medicine materical crude slice purposes in preparing anti-inflammatory drugs described in claim 5.
8. hymsleya amabilis medicine materical crude slice described in claim 5 is preparing the purposes in analgesic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410411862.3A CN105434511B (en) | 2014-08-20 | 2014-08-20 | A kind of hymsleya amabilis medicine materical crude slice and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410411862.3A CN105434511B (en) | 2014-08-20 | 2014-08-20 | A kind of hymsleya amabilis medicine materical crude slice and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105434511A CN105434511A (en) | 2016-03-30 |
| CN105434511B true CN105434511B (en) | 2019-08-20 |
Family
ID=55545445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410411862.3A Active CN105434511B (en) | 2014-08-20 | 2014-08-20 | A kind of hymsleya amabilis medicine materical crude slice and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434511B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108072707B (en) * | 2016-11-16 | 2020-10-16 | 四川辅正药业股份有限公司 | HPLC method for determining content of hemsleyadin A in liquorice-prepared hemsleya amabilis |
| CN108072708B (en) * | 2016-11-17 | 2019-06-14 | 四川辅正药业股份有限公司 | Measure the HPLC method of glycyrrhizic acid content in Radix Glycyrrhizae hymsleya amabilis |
| CN109298121B (en) * | 2017-07-24 | 2020-11-17 | 四川辅正药业股份有限公司 | HPLC method for simultaneously determining content of cucurbitacin and cucurbitacin B in hemsleya amabilis |
| CN108478622B (en) * | 2018-04-16 | 2021-05-07 | 成都辅正生物科技有限公司 | Composition for preventing and treating oral ulcer and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244069A (en) * | 2008-03-11 | 2008-08-20 | 毛高翔 | Compound hemsleyadin preparation |
| CN103536650A (en) * | 2013-09-23 | 2014-01-29 | 颉垚 | Hemsleya amabilis Chinese medicinal preparation |
-
2014
- 2014-08-20 CN CN201410411862.3A patent/CN105434511B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244069A (en) * | 2008-03-11 | 2008-08-20 | 毛高翔 | Compound hemsleyadin preparation |
| CN103536650A (en) * | 2013-09-23 | 2014-01-29 | 颉垚 | Hemsleya amabilis Chinese medicinal preparation |
Non-Patent Citations (2)
| Title |
|---|
| 甘草制雪胆质量标准研究;张婷婷等;《亚太传统医药》;20180430;第14卷(第4期);第44-47页 |
| 雪胆炮制前后的抗炎镇痛作用研究;李艺丹等;《时珍国医国药》;20171231;第28卷(第8期);第1888-1890页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105434511A (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101199683B (en) | Chinese medicine for treating skin disease and preparing method thereof | |
| CN101862351B (en) | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine | |
| US20100226936A1 (en) | Plant Extract Compositions for Prevention and Treatment of Influenza | |
| CN105434511B (en) | A kind of hymsleya amabilis medicine materical crude slice and its preparation method and application | |
| Li | Chinese herbal medicine | |
| CN100443498C (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN102988764B (en) | Chinese medicinal preparation for resisting coccidiosis and preparation method thereof | |
| CN101269182B (en) | Pharmaceutical composition for treating children's wind-heat cold | |
| CN101810686A (en) | Compatible composition for treating rheumatoid arthritis and preparation method thereof | |
| CN104162058A (en) | Traditional Chinese medicine compound preparation for treating gout and preparation method thereof | |
| CN102579869B (en) | Preparation method of traditional Tibetan medicine composition for treating liver diseases | |
| CN109966379A (en) | A kind of pharmaceutical composition and preparation method thereof for insomnia | |
| CN104474021A (en) | Traditional Chinese medicine composition for treatment of exterior heat and preparation method thereof | |
| CN104367673B (en) | A kind of Chinese medicine composition treating Eimeria species | |
| CN100441166C (en) | Combination of medication of containing medicinal rhubarb and activated carbon or carbo medicinalis | |
| CN104436022A (en) | Hemsleya-macrosperma-containing traditional Chinese medicine composition for treating diabetes mellitus | |
| CN101502536B (en) | Cedar total flavone as well as preparation method and medical use | |
| CN110694025A (en) | Eight-treasure intelligence-benefiting compound and preparation method and application thereof | |
| CN104352672A (en) | Tortoise plastron-containing traditional Chinese medicine composition for treating diabetes | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN103479814A (en) | Traditional Chinese medicine compound for treating gout | |
| CN101564409B (en) | Application of traditional Chinese indian lettuce in preparation of diabetes drugs | |
| CN108498655A (en) | It is a kind of to be used for clearing heat and detoxicating blue gold oral solution and preparation method thereof | |
| CN103751239B (en) | A kind of preparation method and applications of Radix Et Caulis Acanthopanacis Senticosi total glucosides and manyprickle acanthopanax general glycosides formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 610000 No.1, Herui South Road, hi tech Zone, Chengdu, Sichuan Province Patentee after: Chengdu auxiliary Biology Technology Co., Ltd. Address before: Tianchen 611731 Chengdu Road, Sichuan province high tech Zone No. 88 No. 1 No. 203 No. -204 Patentee before: CHENGDU MAIDESHEN MEDICINE TECHNOLOGY CO., LTD. |
|
| CP03 | Change of name, title or address | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160330 Assignee: SICHUAN FUZHENG PHARMACEUTICAL Co.,Ltd. Assignor: CHENGDU FUZHENG BIOLOGY TECHNOLOGY Co.,Ltd. Contract record no.: X2020510000008 Denomination of invention: Hemsleya chinensis decoction piece and preparation method and use thereof Granted publication date: 20190820 License type: Exclusive License Record date: 20200426 |
|
| EC01 | Cancellation of recordation of patent licensing contract | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SICHUAN FUZHENG PHARMACEUTICAL CO.,LTD. Assignor: CHENGDU FUZHENG BIOLOGY TECHNOLOGY Co.,Ltd. Contract record no.: X2020510000008 Date of cancellation: 20211209 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160330 Assignee: SICHUAN FUZHENG PHARMACEUTICAL CO.,LTD. Assignor: CHENGDU FUZHENG BIOLOGY TECHNOLOGY Co.,Ltd. Contract record no.: X2021510000055 Denomination of invention: The invention relates to a snow gall decoction piece and a preparation method and application thereof Granted publication date: 20190820 License type: Common License Record date: 20211214 |